Abstract

Urticaria is a disease triggered by mast cells and characterized by recurrent symptoms such as wheals and/or angioedema. Most patients benefit from treatment with antihistamines (AH) or, if not effective enough, from additional therapy with omalizumab, which leads to significant symptom relief. Here we present a patient with therapy-resistant chronic spontaneous urticaria treated with AH, omalizumab, and glucocorticosteroids. The subsequent recommended therapy according to the current guideline, cyclosporine A, was contraindicated in this patient. Therefore, therapy with dupilumab was initiated, resulting in a complete control of symptoms. In this case report, we present a case of successful dual therapy with omalizumab and dupilumab.

Author Details

Authors

• Viktoria Puxkandl¹
• Wolfram Hoetzenecker¹
• Sabine Altrichter¹,²

Departments

• ¹ Department of Dermatology, Comprehensive Allergy Center, Kepler University Hospital Linz & Johannes Kepler University, Linz, Austria, and
• ² Departement of Dermatology and Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany

Address

Wolfram Hoetzenecker, MD, PhD, Department of Dermatology, Kepler University Hospital Linz & Johannes Kepler University, Comprehensive Allergy Center, Krankenhausstrasse 9, 4020 Linz, Austria
Email: wolfram.hoetzenecker@kepleruniversitätsklinikum.at

Citation